KTTA Pasithea Therapeutics Corp.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1841330 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-84.0%
TTM EPS YoY68.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-88.8%
ROA-82.6%
ROIC (approx.)-414.6%
Asset turnover—
Leverage & solvency
Liabilities / assets5.9%
Debt / equity0.00x
Current ratio15.67x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.78x
Accruals ratio-18.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | $486,559 | $15,062 |
| Cost of revenue | — | — | — | $113,195 | $17,275 |
| Gross profit | — | — | — | $373,364 | -$2,213 |
| R&D expense | $7.98M | $7.20M | $8.10M | $2.67M | — |
| SG&A expense | $12.88M | $7.05M | $7.88M | $9.92M | $4.51M |
| Operating income | -$20.86M | -$14.25M | -$15.98M | -$12.59M | -$4.51M |
| Interest expense | — | — | — | $102 | $508 |
| Pretax income | -$20.43M | -$13.90M | -$15.51M | -$11.73M | -$2.17M |
| Net income | -$20.43M | -$13.90M | -$15.96M | -$13.94M | -$2.17M |
| EBITDA | -$20.82M | -$14.23M | -$15.96M | -$12.58M | -$4.51M |
| EPS (basic) | -2.91 | -12.69 | -0.42 | -1.76 | -0.21 |
| EPS (diluted) | -2.91 | -12.69 | -0.42 | -1.76 | -0.21 |
| Weighted avg. shares (diluted) | 7.03M | 1.10M | 1.23M | 1.26M | 10.40M |
| Banking | |||||
| Net interest income | — | — | — | — | -$508 |
| Balance sheet | |||||
| Cash & equivalents | $55.16M | $6.92M | $16.33M | $33.09M | $52.90M |
| Current assets | $56.46M | $7.37M | $16.69M | $34.08M | $53.30M |
| PP&E, net | — | $122,343 | $141,208 | $125,197 | $20,124 |
| Goodwill | — | $1.26M | $1.26M | $1.26M | — |
| Intangibles | $2.90M | $7.31M | $7.94M | $8.57M | — |
| Total assets | $60.24M | $16.06M | $26.12M | $45.18M | $53.32M |
| Current liabilities | $4.97M | $1.12M | $2.63M | $1.88M | $447,280 |
| Total liabilities | $5.02M | $1.28M | $2.72M | $2.68M | $1.90M |
| Shareholders' equity | $55.22M | $14.78M | $23.40M | $42.50M | $51.42M |
| Shares outstanding | 23.09M | 1.39M | 1.04M | 1.30M | 23.01M |
| Cash flow statement | |||||
| Operating cash flow | -$15.21M | -$13.92M | -$12.81M | -$11.89M | -$3.17M |
| Capital expenditure | — | — | $34,301 | $107,101 | $21,503 |
| Free cash flow | — | — | -$12.85M | -$12.00M | -$3.20M |
| Investing cash flow | $11,000 | — | $75,199 | -$2.30M | -$21,503 |
| Financing cash flow | $63.52M | $4.52M | -$3.73M | -$3.21M | $55.93M |
| Depreciation & amortization | $32,421 | $18,865 | $18,290 | $5,094 | $1,379 |
| Stock-based compensation | $297,467 | $773,693 | $592,269 | $835,064 | $471,250 |
| Share buybacks | — | — | $3.73M | — | — |
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.